Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SPON2



This biomarker is also known as:
  • Spondin-2,
  • FLJ34460,
  • FLJ22401,
  • M-spondin,
  • spondin 2, extracellular matrix protein,
  • DIL1,
  • Mindin,
  • FLJ16313,
  • DIL-1,
  • Differentially expressed in cancerous and non-cancerous lung cells 1,
  • spondin 2,

View in BioMuta


SPON2, also known as spondin-2, is a cell adhesion protein that promotes adhesion and outgrowth of hippocampal embryonic neurons. It binds directly to bacteria and their components and functions as an opsonin for macrophage phagocytosis of bacteria. Spondin-2 is essential in the initiation of the innate immune response and represents a unique pattern-recognition molecule in the extacellular matrix for microbial pathogens. Spondin-2 also binds bacterial lipopolysaccharide.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


Spondin-2 has been identified as potential ovarian cancer biomarkers. In a 2007 study (Simon, I. Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8) Spondin 2, B7-H4, and DcR3 were evaluated for their ability to identify clinical disease. The three novel markers and CA125 were elevated in serum of ovarian cancer patients as compared to normal controls.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. SPON2 alone was not a strong predictor.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.